Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving antic ancer vaccination strategies

MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.

(2017) P. Therasse et al.   JOURNAL OF CLINICAL ONCOLOGY

Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031).

(2017) W. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Axillary lymph node coverage of tangent radiotherapy: Comparison of supine versus prone positioning.

(2017) Gregory M. Thompson et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy

(2012) Kyriaki Ioannou et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dendritic Cell-Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Specific Induction of Immunosuppressive Cells

(2012) Y. Dang et al.   CLINICAL CANCER RESEARCH

Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm

(2012) Constantin N Baxevanis   Expert Review of Vaccines

The future of CpG immunotherapy in cancer

(2012) Behnam Badie et al.   Immunotherapy

The C-terminal decapeptide of prothymosin α is responsible for its stimulatory effect on the functions of human neutrophils in vitro

(2012) Pinelopi Samara et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

(2012) Erika Hamilton et al.   Journal of Translational Medicine

Targeting pattern recognition receptors in cancer immunotherapy

(2012) Nadège Goutagny et al.   Targeted Oncology

Trial Watch

(2012) Lorenzo Galluzzi et al.   OncoImmunology

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

(2012) Erika Vacchelli et al.   OncoImmunology

TLR4 Engagement during TLR3-Induced Proinflammatory Signaling in Dendritic Cells Promotes IL-10-Mediated Suppression of Antitumor Immunity

(2011) D. Bogunovic et al.   CANCER RESEARCH

Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response

(2011) J. Fucikova et al.   CANCER RESEARCH

Immune Adjuvant Efficacy of CpG Oligonucleotide in Cancer Treatment Is Founded Specifically upon TLR9 Function in Plasmacytoid Dendritic Cells

(2011) S. Nierkens et al.   CANCER RESEARCH

TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer

(2011) B. Salaun et al.   CANCER RESEARCH

Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth

(2011) Z. Cai et al.   CANCER RESEARCH

Heat-Shock Induction of Tumor-Derived Danger Signals Mediates Rapid Monocyte Differentiation into Clinically Effective Dendritic Cells

(2011) R. Aguilera et al.   CLINICAL CANCER RESEARCH

Impact of tumour volume on the potential efficacy of therapeutic vaccines

(2011) J. L. Gulley et al.   Current Oncology

Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma

(2011) Sofie Wilgenhof et al.   JOURNAL OF IMMUNOTHERAPY

Toll-Like Receptors in Angiogenesis

(2011) Karsten Grote et al.   TheScientificWorldJOURNAL

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy

(2010) Gerty Schreibelt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Toll-like Receptor 3–Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance

(2010) Arnold I. Chin et al.   CANCER RESEARCH

Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma

(2010) C. Brignole et al.   CANCER RESEARCH

Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors

(2010) Regina Berger et al.   CANCER SCIENCE

TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis

(2010) Manabu Taura et al.   CANCER SCIENCE

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8

(2010) D. Wang et al.   MOLECULAR CANCER THERAPEUTICS

A Novel Class of Immune-Stimulatory CpG Oligodeoxynucleotides Unifies High Potency in Type I Interferon Induction with Preferred Structural Properties

(2010) Ulrike Samulowitz et al.   OLIGONUCLEOTIDES

Prothymosin-  inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction

(2010) A. Mosoian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8+ T cells against prostate cancer cells and defined prostate cancer-specific epitopes

(2010) Eva Wieckowski et al.   PROSTATE

Triggering of Toll-like Receptor 4 Expressed on Human Head and Neck Squamous Cell Carcinoma Promotes Tumor Development and Protects the Tumor from Immune Attack

(2009) M. J. Szczepanski et al.   CANCER RESEARCH

Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells

(2009) A Weber et al.   CELL DEATH AND DIFFERENTIATION

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma

(2009) Jared M. Whitson et al.   INTERNATIONAL JOURNAL OF CANCER

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer

(2009) Susan Feyerabend et al.   PROSTATE

Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway

(2008) Qun Jiang et al.   BMC CANCER

Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC- -dependent mechanism

(2008) A. Paone et al.   CARCINOGENESIS

CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans

(2008) W. N. Haining et al.   CLINICAL CANCER RESEARCH

Twelve immunotherapy drugs that could cure cancers

(2008) Martin A. ‘Mac’ Cheever   IMMUNOLOGICAL REVIEWS

Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF

(2008) Padmanee Sharma et al.   JOURNAL OF IMMUNOTHERAPY

Prothymosin α immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a β-sheet conformation in a sequence-specific manner

(2008) Margarita Skopeliti et al.   MOLECULAR IMMUNOLOGY

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

(2008) H. Navabi et al.   VACCINE